AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32331899 — intervention group
Group type: EXPERIMENTAL
Intervention: TMR conversion at 10 weeks (T10)
Number of subjects: 40
Study 32331899 — intervention group
Group type: EXPERIMENTAL
Intervention: TMR conversion at 12 weeks (T12)
Number of subjects: 40
Study 32331899 — intervention group
Group type: EXPERIMENTAL
Intervention: TMR conversion (any group)
Number of subjects: 40
Study 32331899 — intervention group
Group type: COMPARATOR
Intervention: Component-fed diet (Control)
Number of subjects: 40
Study 33248754 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted regression tree (BRT) models incorporating climate environment variables
Number of subjects: 13431
Study 33248754 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-variable model
Number of subjects: 13431
Study 33715526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g.kg‐1 BM)
Number of subjects: 13
Study 33715526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (0.3 g.kg‐1 BM)
Number of subjects: 13
Study 33715526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 35405112 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition bundle
Number of subjects: 604
Study 35405112 — intervention group
Group type: COMPARATOR
Intervention: Care coordinator
Number of subjects: 604
Study 33548647 — intervention group
Group type: EXPERIMENTAL
Intervention: Bagging-based ensemble neural networks (BGNN)
Number of subjects: 0
Study 33548647 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural network (ANN) and decision tree (DT)
Number of subjects: 0
Study 33548647 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models (general)
Number of subjects: 0
Study 33548647 — intervention group
Group type: EXPERIMENTAL
Intervention: Shapley additive explanation (SHAP) method
Number of subjects: 0
Study 32841751 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy using methylene blue followed by IPL illumination
Number of subjects: 39
Study 32841751 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida antigen immunotherapy using 0.1 ml of candida albicans antigen
Number of subjects: 39
Study 32841751 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving 0.1 ml saline
Number of subjects: 39
Study 32826830 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Selected Rest Interval (SSRI)
Number of subjects: 33
Study 32826830 — intervention group
Group type: COMPARATOR
Intervention: Fixed Rest Interval (FRI)
Number of subjects: 33
Study 32007170 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning biomarker for cancer-specific survival
Number of subjects: 1842
Study 32845808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable steroid-eluting sinus stents
Number of subjects: 181
Study 32845808 — intervention group
Group type: COMPARATOR
Intervention: Nasopore packs
Number of subjects: 181
Study 34114771 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeds consumption (specifically pumpkin seeds)
Number of subjects: 889
Study 34114771 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed preference
Number of subjects: 889
Study 34114771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower preference
Number of subjects: 889
Study 34114771 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing frequency of seeds consumption
Number of subjects: 889
Study 34114771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumpkin seeds consumption
Number of subjects: 889
Study 34114771 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall seeds consumption
Number of subjects: 889
Study 35753969 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based pelvic floor muscle training (PFMT)
Number of subjects: 362
Study 35753969 — intervention group
Group type: COMPARATOR
Intervention: Individual pelvic floor muscle training (PFMT)
Number of subjects: 362
Study 33691158 — intervention group
Group type: EXPERIMENTAL
Intervention: Di(2‐ethylhexyl) phthalate (DEHP) exposure
Number of subjects: 436
Study 33691158 — intervention group
Group type: EXPERIMENTAL
Intervention: Di-iso-butyl phthalate (DiBP) and benzyl butyl phthalate (BzBP) exposure
Number of subjects: 436
Study 35866596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild intermittent hypoxia (MIH) exposure (FiO2: 15%, 3×2 h per day for seven consecutive days)
Number of subjects: 5
Study 35866596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild intermittent hypoxia (MIH) exposure
Number of subjects: 5
Study 34842202 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic early identification of work-related stress (WRS) by a validated instrument, GP awareness supported by a brief training session, patients' self-reflection by instrument completion, GP giving feedback, GP identifying preventive measures
Number of subjects: 271
Study 34842202 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 271
Study 35444577 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognition Individualized Activities Lab (SoCIAL)
Number of subjects: 0
Study 35444577 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 33190032 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 200 mg
Number of subjects: 56
Study 33190032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 33568346 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine-cisplatin (GC), given every 21 days for four cycles
Number of subjects: 237
Study 33568346 — intervention group
Group type: COMPARATOR
Intervention: dose-dense methotrexate-vinblastine-adriamycin-cisplatin (ddMVAC), given every 14 days for four cycles
Number of subjects: 237
Study 33568346 — intervention group
Group type: EXPERIMENTAL
Intervention: COXEN GEM score for GC in GC-treated patients
Number of subjects: 237
Study 33568346 — intervention group
Group type: EXPERIMENTAL
Intervention: COXEN GEM score for ddMVAC in ddMVAC-treated patients
Number of subjects: 237
Study 33568346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled arms (GC and ddMVAC) using GC GEM score
Number of subjects: 237
Study 32564051 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave (ESW)
Number of subjects: 80
Study 32564051 — intervention group
Group type: COMPARATOR
Intervention: Ultrashort wave (UW)
Number of subjects: 80
Study 35589358 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation preparedness intervention
Number of subjects: 0
Study 35589358 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33079133 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic upregulation of IL-6 signaling
Number of subjects: 500199
Study 33079133 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 500199
Study 33079133 — intervention group
Group type: COMPARATOR
Intervention: CRP levels
Number of subjects: 500199
Study 32593918 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation group (14 days after surgery)
Number of subjects: 235
Study 32593918 — intervention group
Group type: COMPARATOR
Intervention: Late rehabilitation group (14 weeks after surgery)
Number of subjects: 235
Study 36099420 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based intervention
Number of subjects: 499
Study 36099420 — intervention group
Group type: COMPARATOR
Intervention: Education-only condition
Number of subjects: 499
Study 36099420 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 499
Study 36099420 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based intervention (for individuals with low pre-intervention risk perceptions)
Number of subjects: 499
Study 34352729 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contraction
Number of subjects: 20
Study 34352729 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contraction at 20° position
Number of subjects: 20
Study 34352729 — intervention group
Group type: COMPARATOR
Intervention: Concentric contraction
Number of subjects: 20
Study 34957976 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose PTX (400 mg TID)
Number of subjects: 40
Study 34957976 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose PTX (200 mg TID)
Number of subjects: 40
Study 34957976 — intervention group
Group type: COMPARATOR
Intervention: Control (no PTX)
Number of subjects: 40
Study 35538448 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddle and sucrose
Number of subjects: 60
Study 35538448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 60
Study 35538448 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddle
Number of subjects: 60
Study 35538448 — intervention group
Group type: COMPARATOR
Intervention: Control (routine blood sampling)
Number of subjects: 60
Study 35636061 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based therapy (VRBT) once a week
Number of subjects: 15
Study 35636061 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiovascular rehabilitation program (CRP)
Number of subjects: 15
Study 34161602 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus diet
Number of subjects: 351
Study 34161602 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 351
Study 34161602 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 351
Study 33378403 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (esomeprazole 40 mg, amoxicillin 1 g, metronidazole 500 mg, clarithromycin 500 mg, twice daily for 14 days)
Number of subjects: 140
Study 33378403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid therapy (esomeprazole 40 mg and amoxicillin 1 g twice daily for 14 days, adding metronidazole 500 mg and clarithromycin 500 mg twice daily in the last 7 days)
Number of subjects: 140
Study 33378403 — intervention group
Group type: COMPARATOR
Intervention: Concomitant therapy
Number of subjects: 140
Study 33378403 — intervention group
Group type: COMPARATOR
Intervention: Hybrid therapy
Number of subjects: 140
Study 35147968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fronto‐orbital band anterior displacement during operation
Number of subjects: 31
Study 35147968 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anterior displacement)
Number of subjects: 31
Study 32157524 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary site surgery
Number of subjects: 3231
Study 32157524 — intervention group
Group type: COMPARATOR
Intervention: Chemo/targeted therapy
Number of subjects: 3231
Study 32157524 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 3231
Study 32157524 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 3231
Study 32157524 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic Black versus White patients
Number of subjects: 3231
Study 32157524 — intervention group
Group type: COMPARATOR
Intervention: Visceral versus bone-only metastases
Number of subjects: 3231
Study 32157524 — intervention group
Group type: COMPARATOR
Intervention: Lowest versus highest income quartile
Number of subjects: 3231
Study 35447085 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB-2019 (two doses, 21 days apart)
Number of subjects: 30174
Study 35447085 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB-2019 (one dose)
Number of subjects: 30174
Study 35447085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30174
Study 35447085 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous exposure to SARS-CoV-2
Number of subjects: 30174
Study 34024504 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling and daily oral nutritional supplement (ONS) containing 33.8 g of protein, 2.2 g EPA, and 1.1 g DHA
Number of subjects: 30
Study 34024504 — intervention group
Group type: COMPARATOR
Intervention: Standard care including dietary counselling and protein supplementation when needed
Number of subjects: 30
Study 34024504 — intervention group
Group type: COMPARATOR
Intervention: Dietary counselling and intended protein/fish-oil supplementation
Number of subjects: 30
Study 32585223 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia (4 intracervical injections of bupivacaine hydrochloride 0.5%)
Number of subjects: 208
Study 32585223 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (fentanyl, propofol, laryngeal mask with sevoflurane maintenance)
Number of subjects: 208
Study 32585223 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 208
Study 32585223 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 208
Study 36216250 — intervention group
Group type: EXPERIMENTAL
Intervention: TiPEEK
Number of subjects: 82
Study 36216250 — intervention group
Group type: COMPARATOR
Intervention: PEEK
Number of subjects: 82
Study 33180175 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin (12.8 ± 5.6 mg/day)
Number of subjects: 13
Study 33180175 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (10.8 ± 6.0 mg/day)
Number of subjects: 13
Study 33180175 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin (D3 receptor)
Number of subjects: 13
Study 33180175 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (D2 receptor)
Number of subjects: 13
Study 33450668 — intervention group
Group type: EXPERIMENTAL
Intervention: Product A (Neocate)
Number of subjects: 0
Study 35725457 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel carbon-fibre adjustable reusable accessory (CARA) for supine positioning
Number of subjects: 220
Study 35725457 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care for supine positioning
Number of subjects: 220
Study 35725457 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel device
Number of subjects: 220
Study 35783867 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinnaoning Capsule (XNNC)
Number of subjects: 240
Study 35783867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 32764878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron administered 5 min before intrathecal injection
Number of subjects: 75
Study 32764878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron administered 15 min before intrathecal injection
Number of subjects: 75
Study 32764878 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 5 min or 15 min before intrathecal injection
Number of subjects: 75
Study 35219167 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue diet (arm A)
Number of subjects: 96
Study 35219167 — intervention group
Group type: COMPARATOR
Intervention: Free diet (arm B)
Number of subjects: 96
Study 32219502 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled combination therapy with carboplatin/paclitaxel plus oregovomab
Number of subjects: 0
Study 32219502 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study 35763763 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 1064
Study 35763763 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD stages 2-5
Number of subjects: 1064
Study 35763763 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR values lower than 50 ml/min/1.73 m2
Number of subjects: 1064
Study 35445718 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with Lucitanib
Number of subjects: 20
Study 35445718 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment with Lucitanib
Number of subjects: 20
Study 33443695 — intervention group
Group type: EXPERIMENTAL
Intervention: Project ACTIVE intervention
Number of subjects: 140
Study 33443695 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 140
Study 34511515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (CI) including non-nutritive sucking (NNS), oral motor stimulation, and oral support
Number of subjects: 44
Study 34511515 — intervention group
Group type: COMPARATOR
Intervention: Non-nutritive sucking (NNS)
Number of subjects: 44
Study 34511515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (CI)
Number of subjects: 44
Study 35811140 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nerve block analgesia via electronic pump
Number of subjects: 294
Study 35811140 — intervention group
Group type: COMPARATOR
Intervention: Single injection analgesia
Number of subjects: 294
Study 32168298 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tirofiban infusion
Number of subjects: 52
Study 35624492 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom approach for simulation-based delirium management training
Number of subjects: 9
Study 35624492 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom approach
Number of subjects: 9
Study 33848675 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (not specified dosage or duration)
Number of subjects: 305
Study 33848675 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 305
Study 33316456 — intervention group
Group type: EXPERIMENTAL
Intervention: PARTICS + Usual Care
Number of subjects: 1200
Study 33316456 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1200
Study 32053634 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowchart-assisted standard resuscitation
Number of subjects: 84
Study 32053634 — intervention group
Group type: COMPARATOR
Intervention: CC-only resuscitation
Number of subjects: 84
Study 36308135 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic-assisted nucleus removal (Group 1 - OVD)
Number of subjects: 204
Study 36308135 — intervention group
Group type: COMPARATOR
Intervention: Basal salt solution plus technique (Group 2 - BSS)
Number of subjects: 204
Study 34719411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride combined with midazolam
Number of subjects: 118
Study 34719411 — intervention group
Group type: COMPARATOR
Intervention: Propofol combined with midazolam (Control)
Number of subjects: 118
Study 32571684 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 48
Study 35713701 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative access cavity (CAC)
Number of subjects: 40
Study 35713701 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional access cavity (TAC)
Number of subjects: 40
Study 35713701 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive access cavity (IAC)
Number of subjects: 40
Study 35713701 — intervention group
Group type: COMPARATOR
Intervention: Without access cavity (Control group)
Number of subjects: 40
Study 35713701 — intervention group
Group type: EXPERIMENTAL
Intervention: Load-to-fracture test (all groups)
Number of subjects: 40
Study 35713701 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-FEA (all groups)
Number of subjects: 40
Study 35713701 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT scans (CAC and TAC)
Number of subjects: 40
Study 34001759 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening training
Number of subjects: 49
Study 34001759 — intervention group
Group type: COMPARATOR
Intervention: Morning training
Number of subjects: 49
Study 34001759 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study 33204084 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS continuation
Number of subjects: 970
Study 33204084 — intervention group
Group type: COMPARATOR
Intervention: ICS withdrawal
Number of subjects: 970
Study 33204084 — intervention group
Group type: COMPARATOR
Intervention: ICS withdrawal in patients with a history of ≥2 exacerbations and blood eosinophil count ≥100 cells/μL
Number of subjects: 970
Study 33204084 — intervention group
Group type: COMPARATOR
Intervention: ICS withdrawal in patients with a history of ≥2 exacerbations and blood eosinophil count ≥400 cells/μL
Number of subjects: 970
Study 36058137 — intervention group
Group type: EXPERIMENTAL
Intervention: Active motion task
Number of subjects: 40
Study 36058137 — intervention group
Group type: COMPARATOR
Intervention: Resting state conditions
Number of subjects: 40
Study 33947367 — intervention group
Group type: EXPERIMENTAL
Intervention: Medi‐Taping
Number of subjects: 110
Study 33947367 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (patient education and physiotherapy)
Number of subjects: 110
Study 34483279 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-Walk intervention (8-week home-based brisk walking with motivational supports)
Number of subjects: 57
Study 34483279 — intervention group
Group type: COMPARATOR
Intervention: Physical activity (PA) education alone
Number of subjects: 57
Study 34483279 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous PA (≥225 minutes per week)
Number of subjects: 57
Study 32227554 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2798745 (TRPV4 antagonist)
Number of subjects: 11
Study 32227554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 35774072 — intervention group
Group type: EXPERIMENTAL
Intervention: TRACE (online communication skills training)
Number of subjects: 10375
Study 35774072 — intervention group
Group type: EXPERIMENTAL
Intervention: INTRO (online communication skills training)
Number of subjects: 10375
Study 33059997 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-125 (125I) brachytherapy, prescription dose 144 Gy
Number of subjects: 140
Study 33059997 — intervention group
Group type: COMPARATOR
Intervention: Cesium-131 (131Cs) brachytherapy, prescription dose 115 Gy
Number of subjects: 140
Study 33059997 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-125 (125I) brachytherapy
Number of subjects: 140
Study 33059997 — intervention group
Group type: COMPARATOR
Intervention: Cesium-131 (131Cs) brachytherapy
Number of subjects: 140
Study 33059997 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-125 (125I) and Cesium-131 (131Cs) brachytherapy
Number of subjects: 140
Study 34077627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 941
Study 34077627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941
Study 34077627 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous UST
Number of subjects: 941
Study 32376640 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention for 3 months
Number of subjects: 160
Study 35437467 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs17580 in TB patients
Number of subjects: 420